1. Recent guidelines from JNC 8 (2014) and ASH (2013) recommend ARBs as first-line treatment for hypertension, especially for patients with compelling indications like diabetes or chronic kidney disease. 2. Irbesartan has higher bioavailability than other ARBs, requiring no dose adjustments in renal, hepatic or elderly patients. Studies show irbesartan more effectively lowers blood pressure compared to losartan, valsartan, and enalapril. 3. The IDNT and IRMA-2 trials demonstrate irbesartan's superior renoprotective effects. IDNT showed a 20-23% reduced risk of doubling serum creatinine or end-